Clinical Trial Update: Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Inotuzumab Ozogamicin plus Rituximab vs investigator's choice in follicular lymphoma was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)
• Rituximab (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, Follicular | Phase 3 | Status: TERMINATED | Results posted: 2018-01-09